Physician profile
Bryan Visser
NPI 1588756340
$713.50
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.99 · 2020: $153 · 2021: $292 · 2022: $59.72 · 2023: $63.50 · 2024: $83.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $147.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $121.20 | 2020-2021 | |
| Piramal Critical Care | $96.93 | 2023-2024 | |
| Collegium Pharmaceutical, INC. | $71.06 | 2019-2021 | |
| Biodelivery Sciences International, INC. | $64.59 | 2020-2021 | |
| Medtronic, INC. | $49.27 | 2021 | |
| Lilly USA, LLC | $44.56 | 2020-2021 | |
| Radius Health, INC. | $33.04 | 2021-2022 | |
| Boston Scientific Corporation | $30.36 | 2021 | |
| Nevro Corp. | $29.52 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $27.98 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $24.56 | 2021 | |
| Biogen, INC. | $22.34 | 2024 | Skyclarys |
| Pacira Therapeutics, INC. | $17.63 | 2019 | |
| Fidia Pharma USA INC. | $15.44 | 2022 | |
| Ferring Pharmaceuticals INC. | $14.55 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $13.94 | 2019 | |
| Upsher-Smith Laboratories LLC | $13.21 | 2020 | |
| Depuy Synthes Sales INC. | $11.90 | 2021 | |
| Lundbeck LLC | $11.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Visser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.